Anthropic to develop its own pharmaceuticals
Anthropic plans to develop its own drugs rather than just providing AI tools for pharmaceutical companies, according to a report from STAT News.
This move follows the launch of Claude Science, a workspace built for life science researchers. Anthropic is now shifting from a tool provider to an active participant in drug development.
Specific program details and therapeutic focus areas have not yet been disclosed.
Related stories
- Anthropic's Akamai bill could reach around $20 billion
- Trump adviser's memo puts Amodei at the root of EA
- Amazon's new plugin runs a seller's store from Claude
- Fears of AI apocalypse crashed into Anthropic's $2T IPO
- At least $1B for outside evaluators inside Anthropic
- A November IPO buys Anthropic time to show Q3 numbers
Comments
No comments yet. Be the first.
Join the conversation
Sign in with Google to leave a comment. Your name and avatar come from your Google profile, and the comment appears after moderation.